Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with oxaliplatin by Zhi-Yu Xiao et al.
Silencing Fas-associated phosphatase 1 expression 
enhances efficiency of chemotherapy for colon carcinoma 
with oxaliplatin
Zhi-Yu Xiao, Wei Wu, Navada Eagleton, Huan-Qing Chen, Jing Shao, Hong Teng, Tian-Hao Liu, 
Zhi-Min Jiang, He-Rui Yao
Zhi-Yu Xiao, Wei Wu, Huan-Qing Chen, Jing Shao, Department 
of Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen 
University, Guangzhou 510120, Guangdong Province, China
Navada Eagleton, Department of Veterinary Physiology and 
Pharmacology, Texas A&M University, College Station, Texas 
77843, United States
Hong Teng, Tian-Hao Liu, Zhi-Min Jiang, He-Rui Yao, 
Department of Oncology, Sun Yat-Sen Memorial Hospital of Sun 
Yat-Sen University, Guangzhou 510120, Guangdong Province, 
China
Author contributions: Xiao ZY and Wu W contributed 
equally and performed the majority of experiments; Eagleton 
N performed statistical analysis and was involved in editing the 
manuscript; Chen HQ, Shao J, Teng H, Liu TH and Jiang ZM 
performed part of experiments; Xiao ZY and Yao HR designed 
the study and wrote the manuscript; Yao HR also provided 
financial support for this work.
Supported by Research grants from the Science and Technology 
Foundation of Guangdong Province, No. 2006B36002010, 
2008B030301092, 2009B030801005; the Foundation of Health 
Department of Guangdong Province, No. A2005226; the 
foundation of Guangzhou Science and Technology Bureau, No. 
2009Y-C011-1; the Natural Science Foundation of Guangdong 
Province, No. 7001592; and the National Natural Science 
Foundation of China, No. 30973505
Correspondence to: He-Rui Yao, Associate Professor, 
Department of Oncology, Sun Yat-Sen Memorial Hospital of 
Sun Yat-Sen University, 107 West Yanjiang Road, Guangzhou 
510120, Guangdong Province, China. yaoherui@163.com
Telephone: +86-20-81332107  Fax: +86-20-81332853
Received: October 5, 2009        Revised: November 10, 2009
Accepted: November 17, 2009
Published online: January 7, 2010
Abstract
AIM: To investigate whether silencing Fas-associated 
phosphatase 1 (FAP-1) expression enhances the efficiency 
of chemotherapy for colon carcinoma with oxaliplatin.
METHODS: Expression of FAP-1 in mRNA and protein 
was detected by reverse transcription polymerase 
chain reaction (RT-PCR) and flow cytometry. Small 
interfering RNA (siRNA) was designed according to the 
FAP-1 mRNA sequence. Cell proliferation was evaluated 
by methyl thiazolyl tetrazolium (MTT) assay. Anenxin 
V- and propidine iodine (PI) were assayed by flow 
cytometry for the detection of apoptosis. 
RESULTS: The expression of FAP-1 was increased 
in SW480 cells after chemotherapy with oxaliplatin. 
Transfection of FAP-1 siRNA into SW480 cells silenced 
the expression of FAP-1 and consequently abolished 
the inhibitory function of Fas/FasL-mediated apoptosis 
pathway, thus increasing the efficacy of chemotherapy 
for colon carcinoma with oxaliplatin. 
CONCLUSION: RNA interference combined with 
conventional chemotherapy is more effective against 
colon cancer.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
The incidence of  colon carcinoma is increasing world­
wide[1]. Although great achievements have been made in 
surgery, chemotherapy and even some novel molecule­
targeted drugs, such as bevacizumab (Avastin) used 
in treatment of  colon carcinoma, their efficacy is still 
limited[2]. Since tumorigenesis is a multiple step event 
involving multiple genes, a single treatment modality just 
targets a part of  the pathogenesis of  colon carcinoma. 
The mechanism underlying the limited efficacy of  the 
above treatment modalities still needs to be further 
explored in order to prolong the survival time of  such 
patients. 
Fas/FasL system is the essential pathway of  cytotoxic 
T lymphocytes (CTLs) and natural killer (NK) cells 
to induce cell apoptosis[3]. Fas, an apoptotic message 
receptor, is belonged to the tumor necrosis factor family 
and expressed in many normal tissues and malignancies. 
Its expression pattern is mainly located in activated T 
lymphocytes and NK cells. By binding to Fas antibody 
or FasL, Fas­induced apoptotic pathway can be activated, 
initiating tumor cell apoptosis[4­6]. However, it has been 
reported that Fas receptors are highly expressed in 
colon carcinoma cells at both mRNA and protein levels, 
and FasL levels are high in blood and tissues of  colon 
carcinoma patients[7,8], suggesting that colon carcinoma 
cells can escape from the immune clearance, resist to the 
cytotoxic activity of  host immunocytes, and are, thus, 
insensitive to FasR­ mediated apoptosis. Although the 
mechanism underlying the failure of  immune system 
to protect humans against colon malignancies remains 
unclear, it has been recently shown that Fas­associated 
phosphatase 1 (FAP­1) may play an important role in 
the pathogenesis of  colon malignancies[9]. FAP­1, a 
tyrosine phosphatase, inhibits FasR­mediated apoptosis. 
By interacting with the cytoplasmic death domain of  
Fas receptors, FAP­1 acts as a negative switch in the Fas 
pathway[10]. Transfection of  FAP­1 into Fas­sensitive cells 
can block FasL­induced apoptosis[11]. Fas and FAP­1 are 
expressed in colon cancer tissue and the expression of  
FAP­1 is associated with resistance against Fas­mediated 
apoptosis and interrupting the correspondence between 
FAP­1 and Fas can reverse the anti­Fas inducing apoptosis 
function of  FAP­1[12]. Down­regulating the expression 
of  FAP­1 by interleukin 2 can promote the sensitivity 
of  colon cancer cells to Fas­induced apoptosis[13] and 
interrupting FAP­1 also increases chemosensitivity to 
certain kinds of  cancer[14], suggesting that FAP­1 can be 
used as a target for treatment of  malignancies. These 
findings lead to a question of  whether interrupting FAP-1 
sensitizes chemotherapy for colon carcinoma.
It has been recently shown that RNA interference 
(RNAi) plays an important role in the treatment of  
malignancies, virus infection, and other diseases[15­19]. 
Small interfering RNA (siRNA) is small in size, and can 
easily infiltrate cell membranes and other structures. 
Its efficiency and specificity are higher than those of  
anti­sense oligonucleotide[20­23]. RNAi may be used as 
a novel gene therapeutic procedure combining with 
chemotherapy for colon carcinoma.
In this study, the expression of  FAP­1 was up­
regulated after treatment with oxaliplatin. Silencing FAP­1 
by siRNA effectively reversed the apoptotic resistance 
and increased the efficacy of  chemotherapy for colon 
carcinoma with oxaliplatin. 
MATERIALS AND METHODS
Colon cancer cell line and culture
Human colon adenocarcinoma cell line SW480, obtained 
from Chinese Type Culture Collection Committee Cell 
Bank (Shanghai, China), was maintained in RPMI­1640 
medium (GIBCO, Grand Island, NY, USA), supplemented 
with 10% heat­inactivated fetal calf  serum (FCS) at 37℃ 
in a humidified atmosphere containing 5% CO2.
FAP-1 siRNA design
Three different sequences of  FAP-1 specific siRNA, 
including positive control glyceraldehyde phosphate 
dehydrogenase (GAPDH) siRNA and negative control 
siRNA, were designed and synthesized by Genepharma 
(Shanghai, China). The sequence of  each siRNA is 
shown in Table 1.
siRNA transfection
siRNA was transfected with a siPORT™ NeoFX™ 
transfection agent (AMBION) following its manufacturer’s 
instructions.
Detection of FAP-1 by reverse transcription polymerase 
chain reaction (RT-PCR)
RNA was harvested from colon cancer cells by extract­
ing Trizol (Invitrogen) following its manufacture’s in­
structions. cDNA was synthesized from 2 μg of  total 
RNA in a 20 μL reaction system containing 0.5 μL of  
PrimeScript™ RTase, 4 μL of  5 × PrimeScript™ buffer, 
0.5 μL of  RNase inhibitor, 1 μL of  Oligo dT, 2 μL of  
dNTP, 11 μL of  RNase free H2O. The mixture was incu­
bated for 60 min at 42℃ and then for an additional 30 min 
at 53℃. The unhybridized RNA was digested with 10 
units of  RNase H at 37℃ for 10 min.
PCR was performed on cDNA using the sense and 
anti­sense primers to amplify FAP­1 and a house keep­
ing gene, GAPDH. All primers were designed accord­
ing to the published sequences: FAP-1: (sense) 5'-AG­
GTCTGCAGAGAAGCAAGAATAC-3' and (anti-sense) 
5'-GAATACGAGTGTCAGACATGG-3'; GAPDH: 
(sense) 5'-AACGGATTTGGTCGTATTG-3' and (anti-
sense) 5'-GGAAGATGGTGATGGGATT-3'.
The PCR conditions were as follows: denaturation at 
95℃ for 5 min, followed by 30 cycles at 94℃ for 30 s, at 
50℃ for 45 s, at 72℃ for 1 min, and a final extension at 
72℃ for 7 min for FAP­1, and denaturation at 95℃ for 
5 min, followed by 30 cycles at 94℃ for 30 s, at 58℃ for 
45 s, at 72℃ for 1 min, and a final extension at 72℃ for 
7 min for GAPDH. Primers were used at a final con­
centration of  0.1 μmol/L each, dNTPs at 50 μmol/L, 
Xiao ZY et al . Silencing FAP-1 enhances chemosensitivity
113 January 7, 2010|Volume 16|Issue 1|WJG|www.wjgnet.com
MgCl2 at 1.5 mmol/L, Taq DNA polymerase at 1.0 μg 
per 50 μL reaction mixture. The 607 bp and 208 bp 
PCR products were the predicted FAP­1 and GAPDH, 
respectively, separated by electrophoresis on 2% agarose 
gel and stained with colloidal gold. The target bands 
were analyzed by densitometry. FAP­1 cDNA was semi­
quantitated by densitometric comparison with GAPDH 
from the same sample.
Immunofluorescence analysis for FAP-1
Approximately 106 cells were incubated with 10 g/mL 
rabbit anti­human FAP­1 polyclone antibody (Santa Cruz) 
for 30 min at 4℃ and washed with PBS containing 2% 
FCS. PE­conjugated secondary goat anti­rabbit antibody 
(Boster, Wuhan, China) was added to the cells for 30 min 
at 4℃. The cells were washed again with PBS containing 
2% FCS and then the intensity of  fluorescence was 
analyzed. Isotype­matched control antibody was used 
to determine the nonspecific binding. A total of  10 000 
cells were examined for each determination. Data were 
expressed as relative fluorescence intensity (RFI = mean 
fluorescence intensity of  cells stained with anti­FAP­1 
pAb/mean fluorescence intensity of  cells stained with 
control pAb).
Cell proliferation assay
Cell proliferation was evaluated by methyl thiazolyl tet­
razolium (MTT) assay. SW480 cells were seeded into a 
96­well plate at the concentration of  3000 cells per well. 
Oxaliplatin (Henrui Co, LTD, Jiangsu Province, China) 
was administrated at a concentration of  5 μg/mL 24 h 
after the cells were plated. The proliferation status of  
SW480 cells was observed at 24, 48, 72, and 96 h, re­
spectively, after treatment with oxaliplatin. Each group 
was quadruplicates and its mean OD value was used to 
represent the proliferation status of  the group. MTT 
(Merck) was dissolved in RPMI 1640 and prepared at 
1 mg/L for use. The medium was removed, the cells 
were washed three times with PBS, and 100 μL MTT 
solution was added into each well and incubated in dark 
at 37℃. Then, the MTT solution was removed and 
100 μL DMSO (Sigma) was added into each well to dis­
solve the remaining formazan by gently shaking the plate 
for 15 min. Finally, a 495 absorption value of  each well 
was obtained with a spectrophotometer (Labsystems 
Dragon).
Detection of apoptosis by flow cytometry
Anenxin V­FITC kit (Bender Medsystems) and propi­
dine iodine (PI) were used to calculate the cells undergo­
ing apoptosis with a flow cytometer (Facscalibur, Becton 
Dickinson). Anenxin V (+) PI (­) represents apoptotic 
cells, whereas Anenxin V (+) PI (+) represents dead 
cells. The procedure was carried out according to the 
manufacturer’s instructions for the Anenxin V­FITC kit.
Statistical analysis
All experiments were performed in triplicate. The results 
were expressed as mean ± SE. Statistical analysis was 
performed by one­way analysis of  variance (ANOVA) 
and comparisons among groups were performed by 
Bonferroni’s multiple­comparison t­test. P < 0.05 was 
considered statistically significant.
RESULTS
Oxaliplatin promoted FAP-1 expression in SW480 cells
To investigate whether FAP­1 is resistant to chemo­
therapy for colon carcinoma with oxaliplatin, RT­PCR 
and flow cytometry were carried out to detect the FAP-1 
expression in SW480 colon carcinoma cells at 0, 24, 48 
and 72 h after chemotherapy for colon carcinoma with 
oxaliplatin. The FAP­1 expression was increased at both 
mRNA (Figure 1A) and protein levels (P < 0.01), and 
reached its peak at 48 h (Figure 1B). 
siRNA silenced FAP-1 expression
siRNA was transfected into SW480 cells with a transfec­
tion agent, siPORT(AMBION). Three sequences of  
FAP­1 siRNA (1709, 6267 and 3264) were designed. 
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Figure 1  Expression of Fas-associated phosphatase 1 (FAP-1) mRNA (A) 
and protein (B) after oxaliplation administration. Oxaliplatin promotes FAP-1 
expression of SW480 cells at 0, 24, 48 and 72 h after chemotherapy. bP < 0.01 
vs 0 h group.
Table 1  siRNA sequence
siRNA From 5' to 3'
FAP-1 siRNA 1709 Sense: CGAAGGAAAGUAAACAUAATT
Anti-sense: UUAUGUUUACUUUCCUUCGGT
FAP-1 siRNA 6267 Sense: CAGGUACAUUAAAGAUGAATT
Anti-sense: UUCAUCUUUAAUGUACCUGGA
FAP-1 siRNA 3264 Sense: GGGAGAUCACCUUAGUGAATT
Anti-sense: UUCACUAAGGUGAUCUCCCTT
GAPDH positive 
control 
Sense: GUAUGACAACAGCCUCAAGTT
Anti-sense: CUUGAGGCUGUUGUCAUACTT
Negative control Sense: UUCUCCGAACGUGUCACGUTT
Anti-sense: ACGUGACACGUUCGGAGAATT
siRNA: Small interfering RNA; FAP-1: Fas-associated phosphatase 1; 
GAPDH: Glyceraldehyde phosphate dehydrogenase.
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Forty­eight hours after transfection of  siRNAs into 
SW480 cells, the FAP­1 expression at mRNA and pro­
tein levels was detected by RT-PCR and flow cytometry. 
The FAP­1 protein was expressed in siRNA 1709 group 
(Figure 2A and C) and at the concentration of  60 nmol/L 
(Figure 2B and D), respectively (P < 0.01). 
FAP-1 siRNA combined with oxaliplatin inhibited 
proliferation of SW480 cells 
To investigate whether FAP­1 siRNA enhances the 
sensitivity of  SW480 cells to oxaliplatin, cell proliferation 
was assayed in 6 groups including negative control group, 
negative siRNA group, siRNA 1709 group, oxaliplatin 
group, oxaliplatin+negative siRNA group, and oxaliplatin 
+ siRNA 1709 group. Transfection was performed when 
the cells were seeded. After 24 h, the culture medium 
was removed and washed three times with PBS and 
oxaliplatin dissolved in the culture medium (5 μg/mL) 
was added. The culture medium was replaced daily to 
keep the consistent concentration of  oxaliplatin. Cell 
growth was observed daily for five days. Transfection 
of  negative siRNA and siRNA into SW480 cells did 
not inhibit cell proliferation. Transfection of  oxaliplatin 
combined with transfection of  negative siRNA reduced 
cell proliferation. The greatest proliferation inhibition 
was found after treatment with oxaliplatin combined with 
transfection of  siRNA 1709 (Figure 3). 
FAP-1 siRNA combined with oxaliplatin increased 
apoptosis of SW480 cells
To investigate whether transfection of  FAP­1 siRNA 
into SW480 cells combined with oxaliplatin increases 
apoptosis of  colon carcinoma cells, the apoptotic rate of  
colon carcinoma cells was detected by flow cytometery 
and Anenxin V and PI immunofluorescence. Transfection 
was performed when the cells were seeded. After 24 h, 
the culture medium was removed and washed three times 
with PBS and oxaliplatin dissolved in culture medium at 
the concentration 5 μg/mL was added and the cells were 
harvested. The apoptotic rate of  the negative control was 
9.56% ± 2.38%, and similar in both siRNA transfection 
groups (P = 0.416). The apoptotic rate of  oxaliplatin com­
bined with siRNA 1709 transfection group was 26.7% ± 
3.67%, which was higher than that of  the oxaliplatin treat­
ment group (P < 0.01, Figure 4), suggesting that oxalipla­
tin promotes FAP­1 expression in SW480 cells. 
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Figure 2  Small interfering RNA (siRNA) silencing FAP-1 expression in siRNA 1709 group (A and C) and at the concentration of 60 nmol/L (B and D). bP < 0.01 
vs 0 h group.
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Figure 3  FAP-1 siRNA increasing the inhibitory effect of oxaliplatin on 
proliferation of SW480 cells.
DISCUSSION
Colon cancer represents a major public health problem, 
resulting in more than 1 million new cases diagnosed 
each year and approximately a half  million deaths 
worldwide. Colectomy is the only procedure that may 
cure colon carcinoma, but the 5­year survival rate mainly 
depends on the stage of  tumor at the time of  diagnosis. 
The majority of  patients with colon carcinoma are at an 
advanced stage beyond surgical treatment when they visit 
a doctor[1]. For patients who cannot be cured by surgery, 
chemotherapy is another important and complementary 
treatment[24]. Among the chemotherapeutic drugs, 
oxaliplatin is commonly used in treatment of  colon 
carcinoma. However, its efficacy, especially in patients at 
advanced stage, is still limited[2].
The main mechanism of  action of  oxaliplatin is 
mediated through the formation of  DNA adducts[25­27]. 
When the platinum compound enters the cells, one 
chloride ligand is dissociated to form a reactive monoa­
quamonochloro complex, which reacts rapidly with 
the guanines on DNA to form monoadducts. The 
subsequent dissociation of  the second chloro ligand 
allows conversion of  the transiently formed monoadducts 
to a variety of  stable diadducts[28,29]. The majority are 
intrastrand diadducts binding to a guanine residue[30,31]. 
Since intrastrand adducts are the most abundant adducts 
and capable of  blocking both DNA replication and 
transcription, they are considered the major cytotoxic 
lesions. As a final result, oxaliplatin induces primary and 
secondary DNA lesions leading to apoptosis of  human 
cancer cells[32].
It has been shown that DNA lesion repair mechanism, 
over­expression of  copper transporters, and enhanced 
drug detoxification result in an increased chemo­
resistance to oxaliplatin[33,34]. However, the mechanism 
may be more complicated. Some researchers hold that the 
major process leading to chemotherapy resistance is the 
ability of  cancer cells to evade cell death signals[35]. In our 
study, the expression of  FAP­1, a negative switch in Fas­ 
mediated apoptosis, was elevated in SW480 colon cancer 
cells after treatment with oxaliplatin. We quantified the 
transcription level only by densitometry rather than by 
RT-qPCR. The role of  MMP7 (matrix metallopeptidase 7) 
and its cross­talk with the FAS/FASL system during the 
acquisition of  chemo-resistance to oxaliplatin have been 
reported[36]. Raymond D[37] also showed that oxaliplatin 
can activate the Notch­1 signaling pathway in colon cancer 
cells and enhance its chemo­resistance to SW480 colon 
cancer cells, indicating that the functional disorder of  the 
Fas apoptosis pathway mediated by FAP­1 elevation may 
protect SW480 cells against apoptosis and is involved in 
chemo­resistance effect.
In our study, since FAP­1 was elevated after treatment 
with oxaliplatin and might account for chemo­resistance, 
the FAP­1 expression was inhibited by RNA interference 
to make clear whether it sensitizes chemotherapy. The 
apoptotic rate of  oxaliplatin combined with siRNA 
transfection was higher than that of  oxaliplatin only. 
The greatest proliferation inhibition was found in the 
group of  oxaliplatin combined with siRNA transfection, 
suggesting that the elevated FAP­1 expression is 
involved in the mechanism enabling SW480 cells to be 
insensitive to oxaliplatin treatment. Based on the fact 
that siRNA used to silence the expression of  FAP­1 
and treatment with oxaliplatin increased the apoptosis 
of  SW480 cells and reduced their proliferation, we can 
develop a novel therapeutic measure to enhance the 
efficacy of  chemotherapy. The similar phenomenon was 
also observed in other malignances. Etodolac, a selective 
cyclo­oxygenase­2, can enhance carboplatin­induced 
apoptosis of  human tongue carcinoma cells by down­
regulating FAP­1 expression[38] and sphingosine kinase 
isoforms can regulate oxaliplatin sensitivity to human 
colon cancer cells through ceramide accumulation and 
Akt activation[39]. Secretase inhibitors have been recently 
used to abrogate oxaliplatin­induced activation of  the 
Notch­1 signaling pathway in colon cancer cells, which 
can enhance chemo­sensitivity[37]. In the present study, 
FAP­1 siRNA combined with oxaliplatin reduced the 
proliferation of  colon carcinoma SW480 cells compared 
with oxaliplatin alone. No study is available so far on 
the Fas/FasL system and FAP-1 interacting to influence 
cell proliferation. We hold that the higher reduction of  
proliferation is due to the enhanced apoptotic rate of  
FAP­1 siRNA combined with oxaliplatin treatment, 
decreasing the number of  cells.
Since the pathogenesis of  colon carcinoma remains 
largely unclear, a variety of  chemotherapies have been 
designed to inhibit tumor growth. So far, no single 
strategy can solve all the complicated problems in the 
treatment of  colon carcinoma. Our study is an attempt to 
integrate gene therapy targeting FAP­1 and conventional 
chemotherapy for colon cancer. 
In conclusion, oxaliplatin increases the expression 
of  FAP­1. RNAi can knockdown FAP­1 and sensitize 
chemosensitivity, and RNA interference combined with 
conventional chemotherapy is more effective against colon 
cancer.
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Figure 4  FAP-1 siRNA enhancing the apoptosis inducing effect of 
oxaliplatin.
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Background
Colon cancer represents a major public health problem, resulting in more than 
one million new cases diagnosed each year and approximately a half million 
deaths worldwide. Chemotherapy is an important and complementary treatment 
modality for colon carcinoma. Among the chemotherapeutic drugs, oxaliplatin is 
a commonly used in treatment of colon carcinoma, but its efficacy, especially in 
patients at advanced stage, is still limited.
Research frontiers
The mechanism underlying oxaliplatin chemo-resistance is complicated. 
DNA lesion repair mechanism, over-expression of copper transporters, and 
enhanced drug detoxification cannot fully explain its mechanism. In this study, 
Fas-associated phosphatase-1 (FAP-1) was elevated in colon carcinoma cells 
after oxaliplatin treatment, implicating that the functional disorder of the Fas 
apoptosis pathway mediated by FAP-1 elevation may protect colon carcinoma 
cells against apoptosis and is involved in the chemo-resistance effect. 
Chemotherapy can be sensitized by inhibiting FAP-1 expression with RNA 
interference.
Innovations and breakthroughs
Since the pathogenesis of colon carcinoma remains largely unclear, a variety 
of chemotherapeutic treatment modalities available have been designed. So 
far, no single treatment modality can solve all the complicated problems. This 
study is an attempt to integrate gene therapy targeting FAP-1 and conventional 
chemotherapy for colon cancer.
Applications
Oxaliplatin can increase the expression of FAP-1. RNAi can knockdown FAP-1 
and sensitize chemosensitivity. This in vitro study showed RNA interference 
combined with conventional chemotherapy is more effective against colon cancer.
Terminology
FAP-1 is a tyrosine phosphatase, which inhibits FasR-mediated apoptosis. By 
interacting with the cytoplasmic death domain of Fas receptors, FAP-1 acts as a 
negative switch in the Fas pathway. Transfection of FAP-1 into Fas-sensitive cells 
can block FasL-induced apoptosis.
Peer review
This study investigated the important factors that inhibit the apoptotic effect of 
oxaliplatin on colorectal cancer cells, which is of significance in the treatment of 
colon carcinoma.
REFERENCES
1 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer 
statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2 Carrato A . Adjuvant treatment of colorectal cancer. 
Gastrointest Cancer Res 2008; 2: S42-S46
3 Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere 
V, Nagata S, Hengartner H, Golstein P. Fas and perforin 
pathways as major mechanisms of T cell-mediated 
cytotoxicity. Science 1994; 265: 528-530
4 Suda T, Nagata S. Purification and characterization of the 
Fas-ligand that induces apoptosis. J Exp Med 1994; 179: 
873-879
5 Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365
6 Halapi E. Oligoclonal T cells in human cancer. Med Oncol 
1998; 15: 203-211
7 von Reyher U , Sträter J, Kittstein W, Gschwendt M, 
Krammer PH, Möller P. Colon carcinoma cells use different 
mechanisms to escape CD95-mediated apoptosis. Cancer Res 
1998; 58: 526-534
8 O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly 
J, Collins JK, Shanahan F. Fas ligand expression in primary 
colon adenocarcinomas: evidence that the Fas counterattack 
is a prevalent mechanism of immune evasion in human 
colon cancer. J Pathol 1998; 186: 240-246
9 Lee SH, Shin MS, Park WS, Kim SY, Kim HS, Lee JH, 
Han SY, Lee HK, Park JY, Oh RR, Jang JJ, Lee JY, Yoo NJ. 
Immunohistochemical localization of FAP-1, an inhibitor of 
Fas-mediated apoptosis, in normal and neoplastic human 
tissues. APMIS 1999; 107: 1101-1108
10 Ungefroren H, Kruse ML, Trauzold A, Roeschmann S, 
Roeder C, Arlt A, Henne-Bruns D, Kalthoff H. FAP-1 in 
pancreatic cancer cells: functional and mechanistic studies on 
its inhibitory role in CD95-mediated apoptosis. J Cell Sci 2001; 
114: 2735-2746
11 Sato T, Irie S, Kitada S, Reed JC. FAP-1: a protein tyrosine 
phosphatase that associates with Fas. Science 1995; 268: 
411-415
12 Yao H, Song E, Chen J, Hamar P. Expression of FAP-1 by 
human colon adenocarcinoma: implication for resistance 
against Fas-mediated apoptosis in cancer. Br J Cancer 2004; 
91: 1718-1725
13 Song E, Chen J, Antus B, Wang M, Xie Y, Yao H, Exton MS. 
Interleukin-2 enhances susceptibility of colon cancer cells to 
FasR mediated apoptosis by up-regulating Fas receptor level 
and down-regulating FAP-1 expression. Int J Immunopathol 
Pharmacol 2000; 13: 113-122
14 Wang B, Zheng WG, Xin XY, Qi RY, Yu YC, Cao YX. 
[Combinative effects of FAP-1 antisense oligonucleotide and 
carboplatin on apoptosis of ovarian cancer cell SKOV3] Ai 
Zheng 2004; 23: 885-889
15 Lieberman J, Song E, Lee SK, Shankar P. Interfering with 
disease: opportunities and roadblocks to harnessing RNA 
interference. Trends Mol Med 2003; 9: 397-403
16 Shlomai A, Shaul Y. Inhibition of hepatitis B virus expression 
and replication by RNA interference. Hepatology 2003; 37: 
764-770
17 Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor 
RB. Small interfering RNAs directed against beta-catenin 
inhibit the in vitro and in vivo growth of colon cancer cells. 
Clin Cancer Res 2003; 9: 1291-1300
18 Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference 
to target cyclin E-overexpressing hepatocellular carcinoma. 
Cancer Res 2003; 63: 3593-3597
19 Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen 
J, Shankar P, Lieberman J. RNA interference targeting Fas 
protects mice from fulminant hepatitis. Nat Med 2003; 9: 
347-351
20 Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, 
Kurreck J. Comparison of different antisense strategies in 
mammalian cells using locked nucleic acids, 2'-O-methyl 
RNA, phosphorothioates and small interfering RNA. Nucleic 
Acids Res 2003; 31: 3185-3193
21 Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko 
A, Malvy C. Comparison of antisense oligonucleotides 
and siRNAs in cell culture and in vivo. Biochem Biophys Res 
Commun 2002; 296: 1000-1004
22 Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. RNA 
interference may be more potent than antisense RNA in 
human cancer cell lines. Clin Exp Pharmacol Physiol 2003; 30: 
96-102
23 Garber K. Better blocker: RNA interference dazzles research 
community. J Natl Cancer Inst 2003; 95: 500-502
24 Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, 
Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. 
Outcome of primary tumor in patients with synchronous 
s tage IV colorecta l cancer rece iving combinat ion 
chemotherapy without surgery as initial treatment. J Clin 
Oncol 2009; 27: 3379-3384
25 Johnson NP, Hoeschele JD, Rahn RO. Kinetic analysis 
of the in vitro binding of radioactive cis- and trans-
dichlorodiammineplatinum(II) to DNA. Chem Biol Interact 
1980; 30: 151-169
26 Butour JL, Mazard AM, Macquet JP. Kinetics of the reaction 
of cis-platinum compounds with DNA in vitro. Biochem 
Biophys Res Commun 1985; 133: 347-353
27 Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of 
cytotoxicity of anticancer platinum drugs: evidence that 
cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-
 COMMENTS
Xiao ZY et al . Silencing FAP-1 enhances chemosensitivity
117 January 7, 2010|Volume 16|Issue 1|WJG|www.wjgnet.com
cyclobutanedicarboxylato)platinum(II) differ only in the 
kinetics of their interaction with DNA. Cancer Res 1986; 46: 
1972-1979
28 Raymond E, Faivre S, Woynarowski JM, Chaney SG. 
Oxaliplatin: mechanism of action and antineoplastic activity. 
Semin Oncol 1998; 25: 4-12
29 Schaller W, Reisner H, Holler E. Kinetic investigation of 
the DNA platination reaction: evidence for a transient 
adduct between deoxyribonucleic acid and cis-platinum(II). 
Biochemistry 1987; 26: 943-950
30 Eastman A. Reevaluation of interaction of cis-dichloro-
(ethylenediamine)platinum(II) with DNA. Biochemistry 1986; 
25: 3912-3915
31 Fichtinger-Schepman AM, van der Veer JL, den Hartog 
JH, Lohman PH, Reedijk J. Adducts of the antitumor drug 
cis-diamminedichloroplatinum(II) with DNA: formation, 
identification, and quantitation. Biochemistry 1985; 24: 707-713
32 Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski 
JM. DNA strand breaks and apoptosis induced by oxaliplatin 
in cancer cells. Biochem Pharmacol 2003; 66: 225-237
33 Desoize B, Madoulet C. Particular aspects of platinum 
compounds used at present in cancer treatment. Crit Rev 
Oncol Hematol 2002; 42: 317-325
34 Chen CC, Chen LT, Tsou TC, Pan WY, Kuo CC, Liu JF, Yeh 
SC, Tsai FY, Hsieh HP, Chang JY. Combined modalities of 
resistance in an oxaliplatin-resistant human gastric cancer 
cell line with enhanced sensitivity to 5-fluorouracil. Br J 
Cancer 2007; 97: 334-344
35 Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic 
I. Matrix metalloproteinase-7-mediated cleavage of Fas 
ligand protects tumor cells from chemotherapeutic drug 
cytotoxicity. Cancer Res 2001; 61: 577-581
36 Almendro V, Ametller E, García-Recio S, Collazo O, Casas 
I, Augé JM, Maurel J, Gascón P. The role of MMP7 and its 
cross-talk with the FAS/FASL system during the acquisition 
of chemoresistance to oxaliplatin. PLoS One 2009; 4: e4728
37 Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty 
PB, Schwartz GK. gamma-Secretase inhibitors abrogate 
oxaliplatin-induced activation of the Notch-1 signaling 
pathway in colon cancer cells resulting in enhanced 
chemosensitivity. Cancer Res 2009; 69: 573-582
38 Mishima K, Nariai Y, Yoshimura Y. Etodolac, a selective 
cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced 
apoptosis of human tongue carcinoma cells by down-
regulation of FAP-1 expression. Oral Oncol 2005; 41: 77-81
39 Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano 
Y, Murate T, Hara A, Ueda H, Nozawa Y, Banno Y. 
Sphingosine kinase isoforms regulate oxaliplatin sensitivity 
of human colon cancer cells through ceramide accumulation 
and Akt activation. J Biol Chem 2009; 284: 10422-10432
S- Editor  Wang YR    L- Editor  Wang XL    E- Editor  Lin YP
Xiao ZY et al . Silencing FAP-1 enhances chemosensitivity
118 January 7, 2010|Volume 16|Issue 1|WJG|www.wjgnet.com
